FHA
BMY.RT

Flagship Harbor Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Flagship Harbor Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,281
Closed -$7K – 1990
2020
Q3 		$7K Buy
3,281
+200
+6% +$571 ﹤0.01% 1463
2020
Q2 		$11K Hold
3,081
– – ﹤0.01% 1342
2020
Q1 		$12K Hold
3,081
– – ﹤0.01% 1183
2019
Q4 		$9K Buy
+3,081
New +$8.01K ﹤0.01% 1385

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Flagship Harbor Advisors's BMY.RT Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 3,281 shares — an estimated $7K sold.

Flagship Harbor Advisors first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $12K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 3,281 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $7K.
  • Flagship Harbor Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Flagship Harbor Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $12K in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.